259726-49-3

Upstream product

• 220033-97-6 (R)-2-((2R,3S,5R,6S)-6-Azidomethyl-3-benzyloxy-5-isobutoxy-tetrahydro-pyran-2-yl)-propionic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 220033-95-4 1-O-tert-Butyl-2-O-benzyl-4-O-p-methoxybenzyl-3,6-dideoxy-6-azido-β-L-glucopyranoside 
• 259726-44-8 1-O-tert-Butyl-2-O-benzyl-4,6-O-p-methoxybenzylidene-3-deoxy-β-L-glucopyranoside 
• 220033-93-2 1,2,4,6-Tetra-O-acetyl-3-deoxy-β-L-glucopyranoside 
• 259726-42-6 1-O-tert-Butyl-2,4,6-tri-O-acetyl-3-deoxy-β-L-glucopyranoside 
• 259726-46-0 1-O-tert-Butyl-2-O-benzyl-3,6-dideoxy-6-azido-β-L-glucopyranoside 
• 220033-94-3 1-O-tert-Butyl-4,6-O-p-methoxybenzylidene-3-deoxy-β-L-gluco-pyranoside 
• 259726-43-7 (2R,3S,5R,6S)-2-tert-Butoxy-6-hydroxymethyl-tetrahydro-pyran-3,5-diol 

Relevant academic research and scientific papers

Design and synthesis of a tetrahydropyran-based inhibitor of mammalian ribonucleotide reductase

A tetrahydropyran-based inhibitor (2) of mammalian ribonucleotide reductase (mRR) has been designed and synthesized based on the heptapeptide, N-AcFTLDADF (1), corresponding to the C-terminus of the R2 subunit of mRR. Inhibition studies revealed that 2 is indeed a competent inhibitor, albeit less potent than 1.